Philips NV Files 6-K Report
Ticker: RYLPF · Form: 6-K · Filed: Nov 4, 2025 · CIK: 313216
Sentiment: neutral
Topics: 6-K, regulatory-filing, operations-update
TL;DR
Philips NV filed a 6-K on Nov 4, 2025, updating its status as of Oct 31, 2025.
AI Summary
Koninklijke Philips NV filed a Form 6-K on November 4, 2025, reporting on its activities as of October 31, 2025. The filing includes information related to its business operations and financial reporting, with its fiscal year ending on December 31st. The company is incorporated in The Netherlands and its principal executive offices are located in Amsterdam.
Why It Matters
This filing provides an update on Koninklijke Philips NV's status and operations for investors and regulatory bodies, reflecting its ongoing business activities.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) providing updated information, not indicating any immediate financial distress or significant new risks.
Key Players & Entities
- KONINKLIJKE PHILIPS NV (company) — Filer
- Royal Philips (company) — Registrant's name in English
- The Netherlands (company) — Jurisdiction of incorporation
- November 4, 2025 (date) — Filing date
- October 31, 2025 (date) — Period of report
FAQ
What is the filing type and date?
The filing type is a Form 6-K, filed on November 4, 2025.
What period does this report cover?
The report is for the period ending October 31, 2025.
Where is Koninklijke Philips NV incorporated?
Koninklijke Philips NV is incorporated in The Netherlands.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
What is the company's primary business classification?
The company is classified under X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844].
Filing Stats: 4,518 words · 18 min read · ~15 pages · Grade level 13.2 · Accepted 2025-11-04 10:55:41
Filing Documents
- a2025q3-philipsquarterlyen.htm (6-K) — 869KB
- gmc_wordmarkx2008xrgb.jpg (GRAPHIC) — 369KB
- philips-logoxblue.jpg (GRAPHIC) — 306KB
- 0001628280-25-048592.txt ( ) — 1799KB
Forward-looking statements
Forward-looking statements and other information
Forward-looking statements
Forward-looking statements This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA*, future restructuring and acquisition-related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, macro-economic and geopolitical changes – including the war in Ukraine and ongoing tensions in the Middle East – as well as measures such as announced and proposed tariffs and trade actions introduced in response to rising global tensions Philips' ability to keep pace with the changing health technology environment Philips' ability to gain leadership in health informatics and artificial intelligence in response to developments in the health technology industry integration of acquisitions and their delivery on business plans and value creation expectations ability to meet expectations with respect to ESG-related matters securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights failure of products